{"nctId":"NCT00536913","briefTitle":"Evaluation of Safety and Efficacy of SymbicortÂ® pMDI, With or Without Spacer, in Children (6-11 Years) With Asthma","startDateStruct":{"date":"2007-09"},"conditions":["Asthma"],"count":107,"armGroups":[{"label":"With Spacer","type":"EXPERIMENTAL","interventionNames":["Drug: Budesonide/formoterol pMDI 40/2.25ug + spacer"]},{"label":"Without Spacer","type":"EXPERIMENTAL","interventionNames":["Drug: Budesonide/formoterol pMDI 40/2.25 ug"]}],"interventions":[{"name":"Budesonide/formoterol pMDI 40/2.25ug + spacer","otherNames":[]},{"name":"Budesonide/formoterol pMDI 40/2.25 ug","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* children 6-11 years, diagnosed asthma treated\n* 6 months, PEF\n* 50% of predicted normal value pre-bronchodilator\n\nExclusion Criteria:\n\n* current systemic glucocorticosteroids usage\n* current respiratory infection\n* any significant disease or disorder as judged by investigator","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","maximumAge":"11 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Urinary Free Cortisol (UFC)","description":"Ratio between the value at the end of treatment and the value at start of treatment, including only patients with values at both baseline and end of treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.86","spread":null},{"groupId":"OG001","value":"1.03","spread":null}]}]}]},{"type":"SECONDARY","title":"Forced Expiratory Volume in 1 Second (FEV1)","description":"Changes in FEV1 from baseline to the mean value at 2 weeks to 4 weeks with the baseline value as a covariate.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.17","spread":"-0.38"},{"groupId":"OG001","value":"0.14","spread":"-0.34"}]}]}]},{"type":"SECONDARY","title":"Morning Peak Expiratory Flow (mPEF)","description":"Change in average value from the run-in to the treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation.Missing data between the first and last entry were estimated using linear interpolation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.70","spread":"24.6"},{"groupId":"OG001","value":"19.50","spread":"25.1"}]}]}]},{"type":"SECONDARY","title":"Evening Peak Expiratory Flow (ePEF)","description":"Change in average value from the run-in to the treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation. Missing data between the first and last entry were estimated using linear interpolation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.00","spread":"27.7"},{"groupId":"OG001","value":"15.30","spread":"23.0"}]}]}]},{"type":"SECONDARY","title":"Asthma Symptoms at Night","description":"Change in average value from the run-in to treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation.Missing data between the first and last entry estimated using linear interpolation. Daily scale:0 = No symptoms; 1 = Mild symptoms; 2 = Moderate symptoms; 3 = Severe symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.20","spread":"0.46"},{"groupId":"OG001","value":"-0.21","spread":"0.39"}]}]}]},{"type":"SECONDARY","title":"Asthma Symptoms at Day","description":"Change in average value from the run-in to treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation.Missing data between the first and last entry estimated using linear interpolation. Daily scale:0 = No symptoms; 1 = Mild symptoms; 2 = Moderate symptoms; 3 = Severe symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.25","spread":"0.43"},{"groupId":"OG001","value":"-0.28","spread":"0.41"}]}]}]},{"type":"SECONDARY","title":"Percentage of Nights With Awakenings Due to Asthma","description":"Change in Percentage of nights with awakenings, average value from the run-in to treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation.Missing data between the first and last entry estimated using linear interpolation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.80","spread":"27.2"},{"groupId":"OG001","value":"-8.20","spread":"23.8"}]}]}]},{"type":"SECONDARY","title":"Use of Rescue Medication at Night","description":"Change in average value from the run-in to treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation.Missing data between the first and last entry estimated using linear interpolation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.21","spread":"0.50"},{"groupId":"OG001","value":"-0.14","spread":"0.38"}]}]}]},{"type":"SECONDARY","title":"Use of Rescue Medication at Day","description":"Change in average value from the run-in to treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation.Missing data between the first and last entry estimated using linear interpolation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.30","spread":"0.56"},{"groupId":"OG001","value":"-0.19","spread":"0.41"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":55},"commonTop":[]}}}